These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 36430837)

  • 1. Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.
    di Meo NA; Lasorsa F; Rutigliano M; Loizzo D; Ferro M; Stella A; Bizzoca C; Vincenti L; Pandolfo SD; Autorino R; Crocetto F; Montanari E; Spilotros M; Battaglia M; Ditonno P; Lucarelli G
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
    Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
    Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
    Reustle A; Menig LS; Leuthold P; Hofmann U; Stühler V; Schmees C; Becker M; Haag M; Klumpp V; Winter S; Büttner FA; Rausch S; Hennenlotter J; Fend F; Scharpf M; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Clin Transl Med; 2022 Jun; 12(6):e883. PubMed ID: 35678045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
    Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
    J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic reprogramming of clear cell renal cell carcinoma.
    Zhu H; Wang X; Lu S; Ou K
    Front Endocrinol (Lausanne); 2023; 14():1195500. PubMed ID: 37347113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma.
    Luo Y; Shen D; Chen L; Wang G; Liu X; Qian K; Xiao Y; Wang X; Ju L
    Aging (Albany NY); 2019 Aug; 11(16):6029-6052. PubMed ID: 31422942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of subtype specific biomarkers of clear cell renal cell carcinoma using random forest and greedy algorithm.
    Wu Y; Han W; Xu D; Wang X; Yang J; Lu Z; Chen X; Ding Y
    Biosystems; 2021 Jun; 204():104372. PubMed ID: 33582210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery.
    di Meo NA; Lasorsa F; Rutigliano M; Milella M; Ferro M; Battaglia M; Ditonno P; Lucarelli G
    Expert Rev Mol Diagn; 2023 Apr; 23(4):297-313. PubMed ID: 36960789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
    Du Y; Wang Q; Zhang X; Wang X; Qin C; Sheng Z; Yin H; Jiang C; Li J; Xu T
    J Exp Clin Cancer Res; 2017 May; 36(1):66. PubMed ID: 28494778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and metabolic hallmarks of clear cell renal cell carcinoma.
    Sanchez DJ; Simon MC
    Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):23-31. PubMed ID: 29959988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
    Weiss RH
    Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 16. Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target.
    Gerlinger M; Santos CR; Spencer-Dene B; Martinez P; Endesfelder D; Burrell RA; Vetter M; Jiang M; Saunders RE; Kelly G; Dykema K; Rioux-Leclercq N; Stamp G; Patard JJ; Larkin J; Howell M; Swanton C
    J Pathol; 2012 Jun; 227(2):146-56. PubMed ID: 22362593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies.
    Qi Y; Wang L; Wang K; Peng Z; Ma Y; Zheng Z; Shang D; Xu W; Zheng J
    Biomed Pharmacother; 2019 Mar; 111():821-834. PubMed ID: 30616081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
    Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
    BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
    Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
    J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.